摘要
目的:探讨无抽搐电休克疗法(modified electroconvulsive therapy,MECT)联合艾司西酞普兰治疗重度抑郁症(major depressive disorder,MDD)的疗效及对血清脑源性神经营养因子(brain-derived neuro-trophicfactor,BDNF)、干扰素γ(interferon-gamma,IFN-γ)、白细胞介素-4(interleukin-4,IL-4)水平的影响。方法:选取MDD患者80例,随机分为对照组(n=40)与观察组(n=40);对照组予以艾司西酞普兰口服治疗,观察组予以MECT联合艾司西酞普兰治疗,两组均连续治疗4周。于治疗前和治疗后行17项汉密尔顿抑郁量表(Hamilton Depression Scale-17,HAMD-17)评分、匹兹堡睡眠质量指数(Pittsburgh Sleep Quality Index,PSQI)评分,并行血清5-羟色胺(5-hydroxytryptamine,5-HT)、BDNF、IFN-γ、IL-4的测定,比较两组疗效和安全性。结果:与对照组相比,观察组总有效率(94.74%)提高,差异有统计学意义(P<0.05)。治疗后,观察组HAMD-17和PSQI评分均显著低于对照组(均P<0.05);观察组血清5-HT、BDNF、IL-4水平均显著高于对照组(均P<0.05),IFN-γ水平及IFN-γ/IL-4(Th1/Th2)比值均显著低于对照组(均P<0.05)。两组不良反应发生率的差异无统计学意义(P<0.05)。结论:MECT联合艾司西酞普兰治疗MDD可提高疗效,具有提高BDNF表达和调节免疫的作用。
Objective: To investigate the efficacy of modified electroconvulsive therapy(MECT) combined with escitalopram in the treatment of major depressive disorder(MDD) and its influence on serum levels of brain-derived neurotrophic factor(BDNF), interferon-γ(IFN-γ), and interleukin-4(IL-4). Methods: A total of 80 patients with MDD were randomly divided into a control group(n=40) and an observation group(n=40). The control group was treated with escitalopram orally, and the observation group was treated with MECT combined with escitalopram. Both groups were treated for 4 weeks. Before and after the treatment, Hamilton Depression Scale-17(HAMD-17) scores, Pittsburgh Sleep Quality Index(PSQI) scores, and serum 5-hydroxytryptamine(5-HT), BDNF, IFN-γ, and IL-4 were measured. The efficacy and safety of the 2 groups were compared. Results: Compared with the control group, the total effective rate of the observation group(94.74%) was increased, and the difference was statistically significant(P<0.05). After the treatment, HAMD-17 and PSQI scores in the observation group were significantly lower than those in the control group(both P<0.05);the levels of serum 5-HT, BDNF, and IL-4 in the observation group were significantly higher than those in the control group(all P<0.05), and the levels of IFN-γ and the ratio of IFN-γ/IL-4(Th1/Th2) were significantly lower than those in the control group(both P<0.05). There was no significant difference in adverse reactions between the 2 groups(P<0.05). Conclusion: MECT combined with escitalopram in the treatment of MDD can improve the efficacy, and increase BDNF expression and regulate immunity.
作者
曹玉婷
刘冬
金晓忠
王瑛
夏恩彩
CAO Yuting;LIU Dong;JIN Xiaozhong;WANG Ying;XIA Encai(Department of Psychiatry,Yancheng Fourth People’s Hospital,Yancheng Jiangsu 224003;Department of Psychiatry,Wuxi Mental Health Center,Wuxi Jiangsu 214151;Department of Laboratory,Yancheng Fourth People’s Hospital,Yancheng Jiangsu 224003,China)
出处
《临床与病理杂志》
CAS
2022年第12期3040-3046,共7页
Journal of Clinical and Pathological Research
基金
盐城市科技计划项目(YK2018052)。